Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease

• Status: Completed
• Trial end date: 2012-08-24
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to examine patterns of brain activity in people who are at risk for memory problems (e.g., Alzheimer's disease or dementia)before and after the medication donepezil. Although genetic testing will be done, the results will not be shared with study participants.

Once the genetic testing is completed subjects may continue to the second phase of the study. During this time they will be asked to take the medication donepezil (which is approved by the FDA for the treatment of Alzheimer's disease).

Donepezil is not FDA approved for healthy volunteers and is therefore considered investigational in this study.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vanderbilt University; Vanderbilt University Medical Center
• Treatments: Donepezil

Criteria

Inclusion Criteria:

• Subjects may report experiencing subjective memory dysfunction, however they must be found by clinical evaluation to have no memory dysfunction

• Neuropsychological test battery in the normal range

• Ages 40-85

Exclusion Criteria:

• Dementia (Mini-Mental State Exam less than 25/30)

• Left-handedness

• Current medication that could influence cognition

• Medical, psychiatric, and neurologic conditions, including cerebrovascular disease or uncontrolled hypertension

• Claustrophobia

• Surgical clips or implants

• Pacemakers or other implanted electronic devices

• History of sheet metal work